Long‐term clinical benefits of Sofosbuvir‐based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa - Archive ouverte HAL Access content directly
Journal Articles Liver International Year : 2020

Long‐term clinical benefits of Sofosbuvir‐based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa

(1) , (2) , (1) , (3, 4) , (5) , (6, 7) , (8, 9) , (10) , (11) , (12) , (13, 14) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Moussa Seydi
  • Function : Author
  • PersonId : 1089634

Abstract

Background: In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire and Senegal using Markov model combining data from the literature with estimates of direct-acting antiviral (DAAs) effectiveness in West and Central Africa. Methods: Disease progression was simulated with and without treatment in fictive cohorts of patients "diagnosed" with CHC in Cameroon (n = 3224), Côte d'Ivoire (n = 9748) and Senegal (n = 6358). Lifetime treatment benefits were assessed using (a) life-years saved (LYS); (b) life-years (LY) avoided in compensated cirrhosis (CC), decompensated cirrhosis (DC) and hepatocellular carcinoma; and (c) comparison of the proportions of patients at each disease stage with and without treatment. Probabilistic and determinist sensitivity analyses were performed to address uncertainty. Results: Sofosbuvir-based treatment would save [mean, 95% confidence intervals] 3.3 (2.5; 5.7) LY per patient in Cameroon, 2.7 (2.1; 4.8) in Côte d'Ivoire and 3.6 (2.8; 6.3) in Senegal. With treatment, approximately 6% (1%) of the patients still alive in each of the study countries would be in the CC (DC) health state 11 (15) years after CHC diagnosis, vs 15% (5%) without treatment. Scenario analysis showed earlier diagnosis and treatment initiation would dramatically improve LYS and morbidity. Conclusion: Sofosbuvir-based treatment could significantly reduce CHC-related mortality and help control CHC-related liver disease progression in West and Central Africa. However, the goal of disease elimination necessitates a substantial decrease in DAAs prices, greater political commitment and increases in both national and external health expenditures.
Fichier principal
Vignette du fichier
Manuscript_accepted_version.pdf (389.72 Ko) Télécharger le fichier
Vignette du fichier
Appendix 1 suppl data_accepted.pdf (787.59 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03121819 , version 1 (26-01-2021)

Identifiers

Cite

Mael Baudoin, Maame Esi Woode, Marie Libérée Nishimwe, Maud Lemoine, Babacar Sylla, et al.. Long‐term clinical benefits of Sofosbuvir‐based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa. Liver International, 2020, 40 (11), pp.2643-2654. ⟨10.1111/liv.14613⟩. ⟨inserm-03121819⟩
89 View
113 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More